retatrutide phase 2 trial results obesity in 28 percent average weight loss Lilly's triple agonist achieves 16.8%

So the next three to five years, if were back in five years time, were going to say the last five years weve witnessed a lot of different mechanisms that are being target with drugs that are now available to us

Risk of Anaphylaxis Among New Users of GLP-1 Receptor Agonists: A Cohort Study

About three-quarters of US states dont cover GLP-1s for Medicaid when used just for obesity, per KFF data

Hypoglycemia and cardiovascular risk: is there a major link

Metabolism Smoothie Recipe (With Mango, Grapefruit, and Cayenne) Need a simple way to support your energy and nourish your body

Some copay cards and patient assistance programs work even if the patients primary insurance doesnt cover the drug